Day 1 | Day 2 | Download Brochure | Print
Tuesday, June 9
7:30 Morning Coffee
A panel of patent attorneys discusses the challenges involved with filing for patents and avoiding intellectual property disputes. They present specific examples to elaborate on how patent litigations are being dealt with in the genomics area. This is followed by a series of presentations given by entrepreneurs and emerging companies sharing their genomic therapies, tools, and technologies.
8:00 Patent Attorney Panel of Experts
Moderator: Kathleen M. Williams, Ph.D., J.D., Intellectual Property Attorney, Partner, Edwards Angell Palmer & Dodge LLP
Protecting your IP and Commercializing Your Technology: The Devil is in the Details
Kathleen M. Williams, Ph.D., J.D., Intellectual Property Attorney, Partner, Edwards Angell Palmer & Dodge LLP
IP Due Diligence - Navigating the Patent Landscape in Getting the Deal Done
Rochelle K. Seide, Ph.D., Vice President, Intellectual Property, Biovail Laboratories International SRL
Cost Effective Portfolio Management
Steven L. Highlander, Ph.D., Partner, Intellectual Property, Fulbright & Jaworski LLP
Discovery, Development, Clinical Monitoring and Therapy
G. Kevin Townsend, J.D., Partner, Lovells LLP - Biography
Emerging companies present their technologies, tools, therapies, and business goals for IP feedback funding and partnering consideration.
9:30 GeneIDs, Inc.
Elena Pushnova, Ph.D., Founder & Chief Executive Officer
DNA Diagnostics and Pharmacogenetic Solutions for Common Psychiatric Disorders and Addictions
Development of common psychiatric disorders and addictions is associated with alterations in multiple genes controlling brain neurotransmission. GeneIDs’ set of DNA tests is designed to identify genetic origin of disease in each individual to provide a pharmacogenetic solution for prevention and personalized treatment of disease, to support clinical trials for FDA approval of pharmaceuticals, and to provide evidence of hereditary predisposition for trials. Genetic testing for common psychiatric disorders and addictions has an $18 billion US market potential.
9:45 LineaGen, Inc.
Michael S. Paul, Ph.D., President & Chief Executive Officer
Autism & Multiple Sclerosis Specialty Diagnostics
LineaGen, Inc. is a Salt Lake City-based specialty diagnostics company that provides innovative tests and services for the earlier and more informative diagnosis of Autism and Multiple Sclerosis. LineaGen will provide diagnostic testing services through a CLIA-certified laboratory, including proprietary tests discovered and developed as a result of LineaGen’s core genetic research programs as well as current standard-of-care tests. Integrated with LineaGen’s laboratory testing will be value-add services including comprehensive, personalized interpretation of test results, secure electronic communication/web portal for reporting and client queries, clinical and genetic counseling for patients, their families, and their physicians, and consultation/advocacy for Third-Party Payor reimbursement.
10:00 Traversa Therapeutics, Inc.
Hans A. Petersen, MBA, President & Chief Executive Officer
Business Development Tools for Platform Technologies
Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of short interfering RNA (siRNA) platform delivery technologies for use by partner RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectious human diseases. The company is generating revenue through therapeutic licensing, collaboration, and reagent distribution agreements while continuing to advance its internal oncology programs. Accomplishing all of these goals has required the careful apportionment of technology rights during the business development cycle, and the use of contractual tools including the differentiation of human therapeutic rights from reagent distribution and animal health rights. The company has further divided the platform technology along exclusive and non-exclusive lines and by gene target and traditional fields of use such as ophthalmology. Legal mechanisms such as confidential gene-target gatekeepers have also been used at Traversa to apportion rights between competing licensee companies while confidentially maintaining the identity of the licensed targets. These tools have allowed Traversa to take a single platform RNAi technology and increase its impact through partnerships while maintaining sufficient rights for its own internal human therapeutic initiatives.
10:15 Networking Coffee Break, Poster and Exhibit Viewing
10:45 KEYNOTE PRESENTATION
Translating Small Genetic Contributions into Large Effects Using Phylogenetic Analyses
Allen D. Roses, M.D., Professor of Medicine, Jefferson-Pilot Professor of Neurobiology and Genetics; Director, Deane Drug Discovery Institute; Senior Scholar, Fuqua School of Business; Member, Duke Institute for Genome Sciences & Policy; President of Shiraz Pharmaceuticals, Inc.
11:30 FEATURED SPEAKER
Multilocus Analysis of Sequence and Genotype Data
Nicholas J. Schork, Ph.D., Director of Research, Scripps Genomic Medicine, Director of Biostatistics and Bioinformatics, The Scripps Translational Science, The Scripps Research Institute
Most diseases of contemporary public health concern, such as diabetes, hypertension, and cancer, are influenced by a number of genetic and non-genetic factors, each with small to moderate effect. Identifying genetic factors via genotyping and sequencing-based association strategies will thus be difficult if the combined effects of these genetic factors are not taken into consideration in a relevant association analyses. This talk will describe ways in which multilocus effects can be accommodated in association analysis strategies.
12:15 Close of Morning Session
12:30 Lunch on Your Own
A panel of venture capitalists will discuss their areas of expertise and share tips on securing funding in the current economic climate. This is followed by a series of presentations given by entrepreneurs and emerging companies in the genomics field seeking funding to develop their technologies and therapies, accompanied by valuable feedback from the panel of experts.
2:00 Venture Capital Panel of Experts
Moderator: Vance Vanier, M.D., Chief Medical Officer, Navigenics; Clinical Faculty Member, Stanford University Medical Center; Former Partner, Mohr Davidow Ventures
Title to be Announced
Evan Ng, J.D., Partner, Dorsey & Whitney LLP - Biography
Investment Opportunities in Preventive Genomics
Vance Vanier, M.D., Chief Medical Officer, Navigenics; Clinical Faculty Member, Stanford University Medical Center; Former Partner, Mohr Davidow Ventures - Biography
Title to be Announced
Garrett Vygantas, M.D., Director, Life Sciences, Burrill & Company
Gemomics: A Time of Merging Opportunities
Ted Driscoll, Ph.D., Claremont Creek Ventures - Biography
Emerging companies present their technologies, tools, therapies, and business goals for funding and partnering consideration.
3:30 Arcxis Biotechnologies
Jay West, Ph.D., Chief Technology Officer, Senior Director of Research
Developing Highly Multiplexed Nucleic Acids Solutions for the Clinical Laboratory
Arcxis Biotechnologies is focused on developing elegant, integrated and compact solutions to molecular diagnostic challenges. From proprietary microfluidics to advanced detection methods; streamlined sample preparation to comprehensive automation technology, we are in the business of making molecular methods more reliable, robust and accessible.
3:45 BioNanomatrix, Inc.
Gary Zweiger, Ph.D., Vice President, Business Development
Imaging DNA: Enabling Routine Testing of DNA Structural Variation and Whole Genome Sequencing
BioNanomatrix is developing unique nanoscale imaging and analytic platforms designed to dramatically reduce the time and cost needed to analyze the genome. The company’s patented technology delivers comprehensive analyses of genomic and epigenomic information with single-molecule sensitivity, while avoiding the fragmentation and complex data reassembly required by other approaches.
4:00 Refreshment Break, Poster and Exhibit Viewing
4:45 Cellecta, Inc.
Alex Chenchik, Ph.D., Chief Executive Officer and Scientific Director
HTS of Peptide Pharmaceuticals in Post-Genome Era
HTS is a revolutionary technology for the rapid testing of thousands of chemical compounds, but it is an overly expensive way to screen arrayed peptides for biological activity. We have developed a high throughput technology for functional screening of hundreds of thousands of bioactive peptide compounds in a cell-based assay. A pooled lentiviral scanning peptide expression library designed from all known extracellular proteins is used to transduce a fluorescent reporter cell line, and cells demonstrating modulation in a specific pathway are isolated by FACS—peptide agonists and antagonists responsible for modulating activity of a specific receptor are then identified by high throughput sequencing. Data will be presented that validate the application of the genome-wide peptide HTS approach based on the combined use of pooled peptide expression libraries and transcriptional reporter cell lines for the discovery of novel peptide modulators that control NF-kB-dependent pathway in cancer cell models. Cell-based screens with pooled peptide effector libraries will provide a unique, cost-effective alternative to existing small molecule drug libraries and could even be used by small research groups for HTS of lead peptide compounds.
5:00 MEDomics LLC
Steve Sommer, M.D., Ph.D., Founder and President
MEDomics: Enabling Massively Parallel Sequenced Base Diagnosis in the Genomics Era
“MEDomics” is personalized medicine in the genomics era. MEDomics is a practice of medicine. MEDomics with a capital is an acronym for mutation expert base diagnosis to support the physician in the practice of MEDomics.
5:15 Emerging Company to be Announced
5:30 Close of The Business of Genomics Conference
Co-located Events: Translating Genomic Knowledge Genotyping Tools Genomic Sample Prep